severe luteinising hormone deficiency
Women's health · 2015–2015
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lutropin alfa Stimulation of follicular development in women with severe luteinising hormone (LH) deficiency as supplementation to recombinant follicle stimulating hormone… | Mar 2015 | Recommended with restriction | input received ACCESS Australia · National Infertility Network |
Who spoke
ACCESS Australia · National Infertility Network
What the PBS pays
$51M in government benefit over 2024–25, across 30,391 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lutropin alfa | $51.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.